Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Deferred Tax Liability (2020 - 2024)

Historic Non-Current Deferred Tax Liability for Xeris Biopharma Holdings (XERS) over the last 5 years, with Q4 2024 value amounting to $6.1 million.

  • Xeris Biopharma Holdings' Non-Current Deferred Tax Liability fell 7023.21% to $6.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.1 million, marking a year-over-year decrease of 7023.21%. This contributed to the annual value of $6.1 million for FY2024, which is 7023.21% down from last year.
  • According to the latest figures from Q4 2024, Xeris Biopharma Holdings' Non-Current Deferred Tax Liability is $6.1 million, which was down 7023.21% from $3.3 million recorded in Q2 2024.
  • In the past 5 years, Xeris Biopharma Holdings' Non-Current Deferred Tax Liability ranged from a high of $20.5 million in Q4 2023 and a low of $442000.0 during Q4 2020
  • Over the past 5 years, Xeris Biopharma Holdings' median Non-Current Deferred Tax Liability value was $3.6 million (recorded in 2022), while the average stood at $4.9 million.
  • In the last 5 years, Xeris Biopharma Holdings' Non-Current Deferred Tax Liability skyrocketed by 110045.25% in 2021 and then plummeted by 7023.21% in 2024.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Non-Current Deferred Tax Liability stood at $442000.0 in 2020, then soared by 1100.45% to $5.3 million in 2021, then tumbled by 31.53% to $3.6 million in 2022, then skyrocketed by 463.31% to $20.5 million in 2023, then crashed by 70.23% to $6.1 million in 2024.
  • Its last three reported values are $6.1 million in Q4 2024, $3.3 million for Q2 2024, and $2.6 million during Q1 2024.